Publications by authors named "G Rondon"
Article Synopsis
- Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk type of B-cell ALL that is difficult to treat effectively with standard therapies, resulting in poor prognoses for patients.
- A multicenter study analyzed the outcomes of adult patients who underwent allogeneic hematopoietic cell transplantation (HCT) in their first complete remission (CR1) for Ph-like ALL, comparing results to those of Philadelphia chromosome positive ALL (Ph-pos) and other B-cell Philadelphia negative ALL (Ph-neg).
- The findings indicated that patients with Ph-like ALL had outcomes similar to Ph-neg ALL after HCT, while Ph-pos ALL patients had significantly better survival rates, suggesting that effective second-line therapies in conjunction with HCT
Acute lower gastrointestinal GVHD (aLGI-GVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation. Although the intestinal microbiota is associated with the incidence of aLGI-GVHD, how the intestinal microbiota impacts treatment responses in aLGI-GVHD has not been thoroughly studied. In a cohort of patients with aLGI-GVHD (n = 37), we found that non-response to standard therapy with corticosteroids was associated with prior treatment with carbapenem antibiotics and a disrupted fecal microbiome characterized by reduced abundances of Bacteroides ovatus.
View Article and Find Full Text PDFBronchiolitis obliterans syndrome (BOS) after hematopoietic cell transplantation (HCT) is associated with substantial morbidity and mortality. Quantitative computed tomography (qCT) can help diagnose advanced BOS meeting National Institutes of Health (NIH) criteria (NIH-BOS) but has not been used to diagnose early, often asymptomatic BOS (early BOS), limiting the potential for early intervention and improved outcomes. Using pulmonary function tests (PFTs) to define NIH-BOS, early BOS, and mixed BOS (NIH-BOS with restrictive lung disease) in patients from 2 large cancer centers, we applied qCT to identify early BOS and distinguish between types of BOS.
View Article and Find Full Text PDFBackground: Patients with B-cell lymphoma and acute lymphoblastic leukemia (ALL) who receive chimeric antigen receptor T-cell (CAR-T) therapy may experience clinically significant cytomegalovirus infection (CS-CMVi). However, risk factors for CS-CMVi are not well defined. The aims of our study were to identify risk factors for CS-CMVi and the association between CS-CMVi and nonrelapse mortality (NRM) in lymphoma and ALL patients after CAR-T therapy.
View Article and Find Full Text PDF